Prostate cancer is the third leading cause of cancer death in men in the United States.
Approximately one of seven men will be diagnosed with prostate cancer in his lifetime. One of 39 men will die of prostate cancer.
Prostate cancer is typically treated with chemotherapy, radiation and surgery. A less aggressive treatment, which has undergone recent clinical studies, involves depleting the patient’s testosterone levels to reduce the prostate cancer growth, and then reintroducing the hormone.
Dr. Samuel Denmeade led the research team at Johns Hopkins University to explore the effects of testosterone on prostate cancer. Prostate cancer patients were deprived of testosterone and then treated with the hormone. In some cases, the cancer cells died completely. About one-third of the patients in the study responded very well to the testosterone treatment.
Listen as Dr. Denmeade joins Dr. Susanne Bennett to share the results of the study and the potential future for testosterone treatment of prostate cancer.
Testosterone Treatment for Prostate Cancer
Research has demonstrated the successful treatment of prostate cancer cells with testosterone.
Additional Info
- Segment Number: 1
- Audio File: wellness_for_life/1701wl5a.mp3
- Featured Speaker: Samuel Denmeade, MD
- Guest Website: Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
- Guest Facebook Account: www.facebook.com/Johns.Hopkins.Medicine
- Guest Twitter Account: @hopkinsmedicine @hopkinsmednews
-
Guest Bio:
Dr. Samuel Denmeade is a professor of oncology and urology at the Johns Hopkins University School of Medicine and co-leader of the Prostate Cancer Program for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer.
Dr. Denmeade earned his MD from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine.
His research interests include prostate and renal cancer, bladder cancer and targeted drug development.
Dr. Denmeade was named the Carolyn and Bill Stutt Scholar by The Patrick C. Walsh Prostate Cancer Research Fund in 2012.
- Length (mins): 26:40
- Waiver Received: No
- Host: Susanne Bennett, DC
Published in
Wellness for Life
Tagged under